Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ENSCthis companyEnsysce Biosciences, Inc.	$0.36	-0.23×	0.73×	0×	0.16×	-85.7%	0.0%	0.0%	0.0%	-316.6%	-320.9%	-337.1%	0.1×	0.39×	-545.69×	1.59×	0.0%	3	-82.13	2	C+
AIMAIM ImmunoTech Inc.	$0.16	-0.13×	-0.19×	20.78×	-0.45×	-2271.9%	-284.1%	-11961.4%	-15861.4%	142.7%	-313.6%	-619.7%	-0.5×	-0.31×	-12.96×	0.53×	0.0%	3	-51.36	2	C
KALAKALA BIO, Inc.	$0.17	-0.17×	0.65×	0×	0.13×	24209.1%	0.0%	0.0%	0.0%	-385.6%	-559.8%	-706.1%	0×	0.32×	-11.95×	3.81×	0.0%	3	-92.87	2	B-
OGENOragenics, Inc.	$0.36	-0.17×	0.2×	0×	-0×	319.2%	0.0%	0.0%	0.0%	-118.9%	-108.5%	-547310.7%	0.03×	-0.01×	-11.91×	5.64×	0.0%	1	-63.79	2	C+
SNGXSoligenix, Inc.	$0.34	-0.63×	1.31×	0×	0.05×	251.4%	0.0%	0.0%	0.0%	-209.4%	-200.5%	-147.7%	0.07×	0.65×	0×	2.39×	0.0%	2	-34.78	3	B
XBIOXenetic Biosciences, Inc.	$1.91	-1.37×	0.5×	1.24×	1.56×	-1576.3%	100.0%	-95.2%	-90.1%	-36.2%	-38.3%	-61.9%	0×	2.94×	0×	8.32×	0.0%	3	-36.91	1	C-
Peer median	—	-0.17×	0.5×	0×	0.05×	251.4%	0.0%	0.0%	0.0%	-118.9%	-200.5%	-619.7%	0×	0.32×	-11.91×	3.81×	0.0%	3	-51.36	2	—